Adaptive Biotechnologies Outlines MRD Separation Plan and Raises Revenue Guidance for 2026
Adaptive Biotechnologies (NASDAQ: ADPT) outlined a plan to separate its Minimal Residual Disease (MRD) business from its Immune Medicine segment during the Q2 2026 earnings call. CEO Chad Robins described it as an exceptional quarter, emphasizing strong MRD performance and strategic clarity. The company also raised its revenue guidance for MRD in 2026 to a range of $268 million to $278 million, reflecting confidence in the segment's growth trajectory following successful execution. The separation plan is expected to streamline operations and potentially unlock value by focusing each business on distinct strategic goals. This move signals Adaptive Biotechnologies' commitment to optimizing its portfolio for long-term shareholder value while capitalizing on MRD demand.
Tickers: $ADPT
Topics: biotechnology business strategy financial performance